← All trials
NCT04862221
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2022
- Primary completion
- Apr 30, 2025
- Completion date
- Jan 31, 2026
- First posted
- Apr 27, 2021
- Last posted
- Nov 22, 2021
- Enrollment
- 160
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Study director
- Medical University of South CarolinaOverall official - principal investigator
- Northwestern UniversityOverall official - principal investigator
- Northwestern UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.